The Week 2 Houston-area and statewide Texas high school football scores from Saturday's games.
Aldine Davis 41, Bush 27
Cypress Park 18, Cypress Creek 12
George Ranch 14, Clear Springs 13
Kempner 32, Worthing 6
Manvel 75, Pasadena Memorial 0
Northbrook 29, Sharpstown 26
North Shore 23, Dallas South Oak Cliff 21
Texas City 21, Yates 14
Wheatley 70, Northside 0
Willowridge 52, Washington 23
SA Brennan 56, SA Taft 7
DeSoto 21, Duncanville 20,
Lockhart 20, Kyle Lehman 17
SA Harlandale 27, SA Edison 7

#creek

The FedExCup Fall series tees off at the The Cliffs at Walnut Cove next week as the PGA Tour's inaugural Biltmore Championship Asheville features plenty of big names.
The Blue Ridge Mountains will serve as a backdrop for U.S. Presidents Cup players Justin Thomas, Jacob Bridgeman and Jackson Koivun, who will be tuning up their games ahead of Medinah after getting the nod from captain Brandt Snedeker earlier in the month.
Also in the field are Billy Horschel and Lucas Glover, players No. 100 and No. 101 in the FedExCup points with less than a dozen events left to play this year. Those who sit inside the top 100 secure Tour cards for 2027, while players ranked 101st through 125th earn conditional status.
Following a couple weeks off, the Tour's action returns with plenty at stake, including a $5 million purse. Here's who else will be teeing off in Arden, North Carolina, next week.
2026 Biltmore Championship full field

#fedexcup #biltmore #fall

In 2024, Catalent tapped direct lenders for a $4.2 billion term loan to fund its acquisition by Novo Holdings. Last month, the drug manufacturer refinanced with a $4.1 billion syndicated loan that it says will cut its annual interest expense by about $100 million.
Catalent's move captures a shift under way in the leveraged finance market, according to a new report from DC Advisory. Redemptions from retail investors are contributing to the erosion of private credit's pricing advantage, creating an opening for banks to win refinancing business.
The problems in the retail private credit market show few signs of abating.
All the largest direct lenders, such as Ares, Apollo and KKR, also run business development companies, the most common form of credit fund aimed at individual investors, all under varying degrees of pressure to redeem investors.
PitchBook LCD reported on Wednesday that investors in Cliffwater's direct lending interval fund sought to redeem 16% of shares outstanding in the third quarter, down from 17% in the prior quarter.

#billion #private

The Princess of Wales looked as fresh, fabulous, and fashionable as ever on Friday morning as she arrived at the Royal Marsden Hospital in London.
Kate returned to the place where she received treatment and learned first-hand how funds raised through her National Three Peaks Challenge and ongoing support will transform holistic care for cancer patients across the UK.
Kate chose a stunning dress by Suzannah London (@ David Cliff / Kensington Palace)
The mother-of-three chose a trending colour for autumn - apple-green - in the form of a chic dress by Suzannah London. The beautiful design featured short sleeves, a subtle portrait neckline, **** on-down detailing, and an elegant front split.
The royal's dress is known as the 'Flippy Wiggle' and she has worn it once before (@ David Cliff / Kensington Palace)

#london #dress #kate #david

The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune and neurological disorders. The suspension, effective August 24, followed three patient deaths caused by severe, life-threatening immune reactions (immune effector cell-associated hemophagocytic syndrome). Novartis is currently conducting a safety review alongside independent monitoring boards. Following the news, Bristol-Myers Squibb Company (NYSE:BMY) voluntarily paused trials for its competing CAR-T treatment, zola-cel, as a precautionary measure after detecting transient inflammatory side effects.
Looking at Q2 2026 earnings, Bristol Myers Squibb is currently demonstrating stronger financial momentum. Bristol-Myers Squibb Company (NYSE:BMY) reported total revenue of $13.0 billion, up 6% year over year, driven by a 15% increase in its Growth Portfolio to $7.6 billion, led by Opdivo, Qvantig, Reblozyl, and Camzyos. Non-GAAP EPS reached $2.04, while net income totaled $3.3 billion, or $4.2 billion on a non-GAAP basis. The company also raised its full-year 2026 revenue guidance from approximately $46.0–$47.5 billion to $49.0–$50.0 billion and increased its non-GAAP EPS outlook to $6.75–$7.00.
Novartis AG (NYSE:NVS), meanwhile, reported Q2 net sales of $14.4 billion, up 3% in U.S. dollars and 1% at constant currencies, supported by Kisqali and Kesimpta, which grew 43% and 32% at constant currencies, respectively. However, generic competition reduced growth by 14 percentage points, while core operating income remained flat at $5.9 billion and GAAP net income fell 19% to $3.3 billion. Novartis reaffirmed rather than raised its full-year guidance, calling for low single-digit sales growth and a low single-digit decline in core operating income.
Overall, Bristol Myers stands out as the stronger financial story this quarter, with its Growth Portfolio offsetting legacy patent-cliff pressures and supporting a guidance increase, while Novartis continues to contend with generic erosion weighing on earnings.
Novartis' bull case rests on strong double-digit growth from high-margin blockbusters such as Kisqali, Kesimpta, and Scemblix, supporting robust Q2 free cash flow of $5.6 billion. However, CAR-T safety setbacks could threaten a key pipeline platform, while intense generic competition has already reduced top-line growth by 14 percentage points.

#billion #novartis

Meghan Trainor celebrated her brother Justin's wedding to Alex with heartfelt posts and family photos
Justin Trainor, a producer and composer, has collaborated on Meghan's albums and lives near her in Los Angeles
Meghan has a close bond with her brothers, even previously setting them up on dates to find a "sister"
Meghan Trainor's brother is married!
The "All About That Bass" singer, 32, shared on Instagram Tuesday, Sept. 8 that her younger brother, Justin Trainor, 30, married his girlfriend, Alex, in a cliffside wedding. In her post, Trainor included behind-the-scenes photos as she got ready for the wedding and added sweet photos of her husband, Daryl Sabara, 34, and their two kids, Barry, 3, and Riley, 5, in their wedding best as all four walked down the aisle during the ceremony.

#wedding #brother #justin #angeles

No withdrawal order eliminates RMDs from a traditional IRA. Only Roth conversions, qualified charitable distributions, or never owning one in the first place can genuinely shrink them.
IRMAA surcharges hit Medicare premiums two years after the income that triggers them, jumping joint filers from $203 to $284 monthly by crossing $218,000 MAGI.
Letting an IRA compound untouched through your 60s forces larger RMDs at 73, often pushing retirees into higher brackets and through IRMAA cliffs simultaneously.
Read More: Avoid these 13 retirement mistakes before they derail your future (sponsor)
A $2.1 million nest egg split evenly between a taxable brokerage account and a traditional IRA can throw off a six-figure income. What most retirees miss is that where each holding sits and when each dollar comes out determine whether Medicare surcharges and a swollen required minimum distribution eat that income a decade later.

#medicare #surcharges #retirees #magi

Vertiv, Applied Optoelectronics, and Innodata entered September well below their 2026 highs despite strong operating growth. The pullbacks do not make them interchangeable bargains. Vertiv Holdings Co. (NYSE:VRT) sells power and cooling, Applied Optoelectronics, Inc. (NASDAQ:AAOI) supplies optical transceivers, and Innodata Inc. (NASDAQ:INOD) provides data engineering and model-evaluation services.
Vertiv's second-quarter sales rose 24% to $3.27 billion, adjusted operating margin expanded 410 basis points to 22.6%, and adjusted free cash flow reached $925 million. The bull case is rising power and thermal content per AI rack. The bear case is project timing, supply congestion, and expectations built around long-duration demand. Insider Monkey counted 112 hedge funds holding Vertiv Holdings Co. (NYSE:VRT) in Q2, up from 96 in Q1. Cliff Asness's AQR Capital reported 2,686,683 shares, 0.5% more sequentially.
Applied Optoelectronics posted record revenue of $191.9 million, while 800G volume more than doubled from Q1. Management expects 800G and 1.6-terabit demand to exceed production capacity through mid-2027. That capacity ramp is the bull case; a 27.7% GAAP gross margin, a $22.8 million GAAP loss, customer concentration, and execution are the bear case. Fifty-four hedge funds held Applied Optoelectronics, Inc. (NASDAQ:AAOI), down from 55. Value Aligned Research disclosed 1,595,124 shares, 26% more sequentially.
Innodata's revenue grew 58% to $92.1 million and adjusted EBITDA rose 92% to $25.4 million. Its reusable data sets and evaluation work can expand margins, but large-customer dependence and rapidly changing model-training methods create risk. Twenty-five hedge funds held Innodata Inc. (NASDAQ:INOD), up from 20. Mitch Rubin's RiverPark Advisors reported 2,042 shares, 18% more than in Q1.
AAOI's August 14 short-interest settlement showed 10,421,985 shares sold short, equal to 12.81% of float, with 0.69 days to cover..The elevated short-float percentage signals substantial bearish positioning, while the low days-to-cover ratio suggests shorts could cover relatively quickly at recent trading volumes.Vertiv has the strongest cash generation, AAOI the sharpest capacity upside, and Innodata the lightest physical footprint. A buying opportunity exists only if margins, customer diversification, and cash conversion justify each stock's remaining expectations. The risks also differ in timing. Vertiv can lose on delayed data-center construction, AAOI can lose during the manufacturing ramp, and Innodata can lose when a major customer changes vendors or training methods. Investors should therefore avoid using distance from a high as valuation ******* ysis. Order conversion, gross-margin durability, customer concentration, and diluted share growth are the comparable checkpoints. The pullback improves entry prices, but only operating evidence can establish value. Balance-sheet resilience matters most when capacity plans meet a weaker cycle.

#innodata

After years as both an actor and a screenwriter, Cliff Dorfman is ready to set the stage for the next phase of his Hollywood career with his most personal project to date.
Dorfman, 58, rose to prominence in the 1990s with supporting roles on "Beverly Hills, 90210," among other shows. After shifting his focus to screenwriting, he wrote 14 episodes of HBO's "Entourage" and co-wrote the screenplay for the 2011 feature film "Warrior," starring Tom Hardy.
Buzz: Jameela Jamil Declares Botox A 'Prison' For Women: 'We Have Lost A Grip On Reality'
Despite those accomplishments, Dorfman says, he never had a chance to "understand my own story — and to survive it" until he wrote "Crime Family," his debut novel. Published in July, the 287-page thriller follows Chase Forman, a Hollywood writer who returns to his native Long Island, New York, to **** ist his family as his adoptive father's health and mental acuity decline.
Though Chase has spent most of his adulthood distancing himself from the Formans, he soon discovers that his family is part of an organized crime empire, with his adoptive mother, Helene, personally overseeing an international money-laundering operation. What follows is a gripping bicoastal chase as Chase and his family members become fugitives on the run from the FBI.

#family #dorfman #adoptive #cliff

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
The flagship private credit fund of Cliffwater LLC capped redemptions at 5% in Q3 after investors asked to redeem approximately 16% of shares.
Cliffwater Corporate Lending Fund told shareholders in a letter Thursday that it would fulfill approximately one-third of redemption requests, according to a shareholder letter seen by Bloomberg.
Cliffwater's Chief Executive Officer Stephen Nesbitt said in the letter the firm "remains committed to acting in the best interests," of its shareholders. Nesbitt added that investors who have requested cash since Q1 have received approximately 78% of capital.
Read Also:Brookfield Could Pull $600 Million From HomeServe in Debt Deal

#investors #benzinga

Sept 03, 2026, 1:00 pm EDT
Estimating the U.S. national debt as a percentage of economic growth seems to have become something of a national pastime—one that is moving beyond data nerds.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Blackstone and Cliffwater have seen redemption requests of about 10% and 16%, respectively, at their private credit funds.

#rights #reserved

Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below.
Ray Dalio is best known for founding one of the world's largest hedge funds, Bridgewater ****** ociates and for predicting the 2008 financial crisis. Now, Dalio has a new warning to share and it's one investors should heed (1).
While Dalio wrote a book laying out his concerns, he's also prepared a CliffNotes version published by Time and announced in an X post, stating, "I squeezed my explanation of the debt supply and demand problem into a 3-minute read, so it's my best, few-minute explanation of this problem (1)."
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
JPMorgan sees gold hitting $5,000/oz by Q4 — and savvy investors are protecting their wealth with a tax-advantaged Gold IRA. Get your free guide from Priority Gold

#problem #minute #wealth

Most college golfers spend four years grinding on the mini-tours, hoping for a single shot at the big leagues. Tyler Jones just got that shot without waiting a single day. The reigning Southern Conference Men's Golfer of the Year has secured a sponsor exemption to the PGA Tour's inaugural Biltmore Championship. This marks a historic moment for Western Carolina University golf, as Jones becomes the first active Catamount to compete in a PGA Tour event, breaking a barrier that has stood for decades.
The details of this opportunity are specific and significant. According to the official release from catamountsports.com, Explore Asheville and Biltmore Estate granted the exemption. Three tournament victories during a breakthrough 2025-26 campaign earned Jones this spot. His standout performance came at the J.T. Poston Invitational, where he claimed an individual ***** le at the Waynesville Inn & Golf Club. Scheduled for Sept. 17-20 at The Cliffs at Walnut Cove, a Jack Nicklaus Signature Design course, the event itself is set there. For the first time since 1942, this tournament marks the PGA Tour's return to the mountains of western North Carolina. Coverage will be extensive, featuring Golf Channel, PGA TOUR LIVE on ESPN+, SiriusXM, and the PGA TOUR World Feed. Jones will also share the field with Western Carolina alumnus J.T. Poston, a four-time PGA Tour winner. That connection creates a full-circle moment for the program as it rises on the national stage.
The emotional weight of this achievement is clear in the words of the program leadership. Head coach Tim Eckberg, who is also an alumnus, spoke directly to the significance of the moment. "This is a massive day for Tyler and for Catamount golf," Eckberg said. He added that the opportunity fills him with pride, noting that the success stems from what J.T. Poston has accomplished and the hard work the current young men continue to put in. The coach emphasized that the program is finally being recognized for opportunities that were previously out of reach. Eckberg also highlighted the broader impact on the student-athlete. "He represents WCU exceptionally well as a student-athlete," the coach stated. "Tyler is an incredible talent, and he showed that throughout last season," Eckberg noted, adding that "His game is ready for this next challenge." The program also extended gratitude to the sponsors who made this possible. "A huge thank you goes to Biltmore and Explore Asheville for believing in Tyler and our program," the coach said. This support validates the years of development within the Catamount system.
From an insider perspective, this exemption signals a shift in how the Tour integrates local talent with regional events. The Biltmore Championship Asheville is designed to bridge the gap between the collegiate level and the professional tour in a specific geographic market. By bringing in a local star like Jones, the organizers ensure that the narrative of the tournament includes the very commu

Pfizer (NYSE: PFE) has faced several issues in recent years that have weighed on its share price. First, the company's coronavirus business isn't nearly as strong as it once was. Second, Pfizer is racing toward important patent cliffs, including that of Eliquis, an anticoagulant. Third, the pharmaceutical giant has faced clinical setbacks with otherwise promising pipeline candidates, including some it acquired. This problem has led to billions in impairment charges. Because of these headwinds (and others), Pfizer's shares have lagged broader equities over the past two years and have hovered below $30 apiece. Is it finally time to invest in the company? Let's see whether there is a rebound on the horizon.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Let's start with Pfizer's recent second-quarter update. The company's revenue increased by 1% year over year to $15 billion. While that top-line growth doesn't look impressive, it beat ***** yst estimates. On the bottom line, Pfizer's adjusted earnings per share were $0.77, slightly lower than the $0.78 reported in the prior-year quarter. Here too, Pfizer beat expectations. And it's important to highlight what drove the revenue and earnings beat.
The company noted that non-COVID revenue increased 5% year over year, while sales from launched and acquired products jumped 18%. This is great news for Pfizer. It suggests that newer (and acquired) products will help pull sales in the right direction over the medium term, while older medicines, especially within its coronavirus business, continue to lose steam.
Even with the progress Pfizer is making with relatively new launches, upcoming patent cliffs will be a major problem for the company. Consider, for instance, that Eliquis was the drugmaker's best-selling therapy during the second quarter. Pfizer's revenue from Eliquis came in at $2.4 billion, up 21% year over year. So, it arguably remains its single most important growth driver. Pfizer will have to launch more new drugs to fill the gap Eliquis will leave behind as it faces generic competition by the end of the decade. Can the company pull it off? My view is that it can.

#company #revenue #years

On August 12, Royalty Pharma (NASDAQ:RPRX) agreed to pay Zealand Pharma $100 million for the rights to future royalties on rusfertide, an experimental treatment for a rare blood disorder called polycythemia vera. It is Royalty Pharma's second collaboration with Zealand, and it arrives just as rusfertide awaits a decision from the FDA. For a company that makes its living buying pieces of other companies' drugs, the timing says a lot about how it weighs risk against reward before a regulatory verdict even lands.
Royalty Pharma's business depends on picking the right moment to buy into a drug's future, and this deal fits that pattern. Under the agreement, $50 million changes hands at closing and the remaining $50 million arrives on the first anniversary, in exchange for a 1% royalty on rusfertide's global sales plus any regulatory and commercial milestones. Rusfertide, a once-weekly self-injected therapy that mimics the hormone hepcidin to control iron levels in polycythemia vera patients, already has an FDA goal date set for the third quarter of 2026, with Takeda lined up to handle commercialization worldwide. That is a near-term catalyst most royalty purchases do not carry.
The broader portfolio backs up the confidence. Royalty Receipts grew 14% to $768 million in the second quarter of 2026, lifted by Tremfya, Voranigo, Imdelltra and Evrysdi, and the company raised its full-year 2026 guidance for Portfolio Receipts to a range of $3.4 billion to $3.5 billion, the second increase this year. Capital deployment has already topped $1 billion in 2026, including a July 2026 royalty purchase tied to AstraZeneca's cliramitug, pushing the development-stage pipeline to 19 potential therapies. Even after repaying a $380 million term loan in July 2026, Royalty Pharma still paid a quarterly dividend of $0.235 per share and bought back $45 million of stock in the second quarter alone.
Not every royalty ages well, and Royalty Pharma's own numbers show it. Promacta royalties fell 75% in the second quarter of 2026 to just $8 million as US generic competition took hold, and Imbruvica payments slipped 16% to $36 million, a reminder that patent cliffs eventually catch up to even the steadiest cash flows. That same risk sits underneath every new deal the company signs, including the one with Zealand.
The rusfertide agreement carries its own strings. Royalty Pharma's 1% royalty stops scaling once global sales pass $1.5 billion, at which point Zealand keeps a 0.25% cut and Royalty Pharma only 0.75%, so the largest commercial outcomes get split rather than fully captured. And rusfertide still has not cleared the FDA. The agency's goal date only falls in the third quarter of 2026, meaning the second $50 million payment is committed before regulators finish their review. Layer that onto a balance sheet carrying $9.2 billion in total debt principal against $812 million of cash as of June 30, 2026, and it becomes clear this is a company funding new bets with borrowed as w

Katie Meyer's No. 19 will officially be the first jersey number retired in Stanford women's soccer history.
The former standout goalkeeper will be honored during a ceremony before the Cardinal's home match against USC on Thursday. Meyer, who played for Stanford from 2018 to 2021, died by suicide in March 2022. The two-time team captain helped lead the Cardinal to the 2019 national championship.
"Katie was an extraordinary competitor, an exceptional leader and, most importantly, an incredible person who had a profound impact on everyone around her," Stanford women's soccer coach Paul Ratcliffe said in a statement. "She played the game with such passion and courage, and she brought a joy and energy to our program that was uniquely Katie.
"Retiring the No. 19 is a meaningful way for us to honor her legacy and ensure that future generations of Stanford women's soccer players understand the impact she had on this program, this university and the people who had the privilege of knowing her."
According to Stanford athletics, the match against USC will also serve as the school's annual Mental Health Awareness match. The Cardinal will distribute "Mental Health Matters" hats to fans in attendance, and various on-campus organizations will be present to promote mental health awareness and emphasize the importance of supporting people who may be struggling.

#Health

More than ever before, college sports are a business for everyone involved.
That money has to come from somewhere, and many schools are finding creative ways to get it. Here are some of the corporate sponsorships funding NIL and other expenses around the Big 12.
In July, Texas Tech announced a 15-year agreement with Galaxy, a data center infrastructure company, to rename Jones AT&T Stadium to Galaxy Stadium.
The former name honored the school's third president, Clifford B. Jones, who donated $100,000 to help fund the construction of the stadium in 1947.
"It goes without saying college athletics continues to evolve," Texas Tech AD Kirby Hocutt told Sports Business Journal. "I look at that as a very exciting opportunity and challenge to reinvent athletic administration, college athletics and how we continue to build toward a commercial media type of organization."

#Tech #athletics

Steel and aluminum stocks surged and then retreated last week as the escalating trade war between the United States and Canada sent investors scrambling to reprice exposure to North American metals supply chains.
SLX gained 1.6% on Monday, Aug. 25, following the breakdown of U.S.-Canada trade talks, and the State Street Materials Select Sector SPDR (XLB) reached a new intraday record that session, topping the peak it had set in February. Shares of Nucor, Steel Dynamics, Cleveland-Cliffs, and Century Aluminum all climbed. The gains proved short-lived, however: by Friday's close, XLB had slipped into the red for the week and SLX was essentially unchanged, according to CNBC. Through Aug. 28, Morningstar data show SLX has gained more than 28% on the year and XLB more than 18%.
The swing reflects the complexity of a trade war between two countries whose metals industries are deeply intertwined. Dan Luttner, who serves as managing partner of the supply chain consulting firm NEOS by Argon & Company, characterized the initial stock move to CNBC as a repricing reflex rather than a durable signal. "The stock pop is a headline reflex, honestly — mills reprice to replacement cost the second a 50% wall goes up, so of course Nucor and Cleveland-Cliffs jumped," Luttner said. "But that's not the interesting question. The interesting question is who controls their feedstock inside the wall versus who's still exposed to it?"
Luttner noted that both Nucor and Cleveland-Cliffs use electric arc furnace technology whose inputs have no dependence on Canadian ore or slab, positioning them to capture tariff-driven pricing benefits without the same exposure. Cleveland-Cliffs stock is nonetheless in negative territory for 2026 because of balance sheet stress. Century Aluminum is a more complicated case: because domestic primary aluminum production is thin, the raw inputs that sustain it — alumina and semi-finished material — largely still flow across the Canadian border, undermining the protection the tariffs were meant to provide.
Atsi Sheth, chief credit officer at Moody's Ratings, said uncertainty will persist. "Expect much more of this uncertainty for some time to come," Sheth said. She added that U.S. steel companies hold a modest edge over their Canadian counterparts because the U.S. market is larger, but said the auto sector has no clear winner given how deeply integrated cross-border production is.

#cliffs #nucor

A safe 3.5% withdrawal on $1.6 million yields somewhere between $52,000 and $56,000 gross, but taxes and pre-Medicare health insurance shrink real spending power to roughly $35,000 annually.
Enhanced ACA premium tax credits expired January 1, 2026, restoring the 400% federal poverty line cliff and potentially costing early retirees tens of thousands per year in premiums.
Once Social Security kicks in between ages 67 and 70 alongside Medicare, the equation flips, letting the same $1.6 million portfolio support roughly double the lifestyle it funded during the bridge years.
Read More: Learn 7 ways to generate income with a $1,000,000+ portfolio (sponsor)
You are 61. You have $1.6 million across retirement and brokerage accounts. You want to stop working now, but Social Security is six to nine years away depending on when you claim. Until then, the portfolio carries every dollar of spending, every health insurance premium, and every tax bill. That is a heavier lift than most people realize.

#million #Social #roughly

A Nashville charter school has removed books featuring LGBT themes from its elementary school libraries months after a Christian teacher was disciplined for refusing to read one of the books to students, a decision the school later cleared from the teacher's record.
The Tennessee Star reported Friday that, according to the First Liberty Institute — a nonprofit legal organization — the Knowledge is Power Program (KIPP) in Nashville has taken out books that promote same-sex marriage.
"We are thrilled that KIPP Nashville voluntarily removed books that could run afoul of parents' rights under the Constitution and Tennessee law," Cliff Martin, senior counsel at First Liberty Institute, said in a Thursday statement.
"It is paramount that religious views be respected in schools," Martin said.
Utah Library Confirms Lgbtq 'Pride' Book For Its 'Smallest Patrons' Is Kept Easily Accessible

#liberty

I'll keep this one short: The Green Bay Packers target their pre-draft visitors at a high clip, whether it's the draft, as initial undrafted free agents or further down the line. For example, last cutdown cycle the team traded a pick for offensive linemen Darian Kinnard and picked up tight end Josh Whyle to the practice squad. Whyle eventually ended up winning a roster spot and made this year's initial 53-man roster.
So, who was just made available to the Packers all at once? Good question. So far (every team hasn't officially announced their roster yet), these are the players who just hit the market and were brought to Green Bay during their draft cycle (since 2022, when the team started targeting more draft picks).
Hendon Hooker, **** ans
Sean Clifford, Bengals
Can I interest anyone in Sean Clifford as a QB3 again?

#team #initial

Tom Felton reflected on what went into filming the Harry Potter epilogue for 2011's Deathly Hallows — Part 2 time jump
Fifteen years later, he is currently reprising the role of Draco in the Harry Potter and the Cursed Child stage play on Broadway
The actor joked that his current appearance in 2026 is "more flattering" than the version of adult Draco in the film
Tom Felton is reflecting on what it was like to film the epilogue for Harry Potter and the Deathly Hallows — Part 2.
Fifteen years after the final Harry Potter film was released in 2011, Felton, 38, said that the epilogue time jump required "a lot of research into what we would look like 19 years later." The epilogue showed the main characters — including Felton's Draco Malfoy, Daniel Radcliffe's Harry Potter, Rupert Grint's Ron Weasley and Emma Watson's Hermione Granger — as adult parents sending their children to Hogwarts.

#epilogue #draco #film

PRAIRIE VIEW - State championships aren't won in the heat and humidity of late August.
Brian Randle and his players have a more lucid understanding of that reality than most. The Randle High School football program has ended each of its past two seasons with a high-stakes game right before Christmas.
With 16 more weeks remaining before the UIL hands out its gold-plated plaques in Arlington, the Lions are embracing the journey. They're calling this season "The Reckoning," and it's started with a momentous victory.
This campaign was never going to be about one opponent. Randle is simply 1-0 after Friday night's 20-14 triumph against Dallas powerhouse South Oak Cliff. But in a rubber match between the programs that have faced off for the past two Class 5A Division II state **** les, taking care of the Golden Bears was the first order of business.
"I mean, we had to break the tie," said Randle, whose team avenged a 35-19 loss from last December's championship game and is now in Class 5A Division I. "We had to break the tie. It's funny because I love what Dallas does. I love what SOC does. But their fans, they talk a lot. So it feels good to have bragging rights for another 12 months until we meet again."

#past

Following the Chargers' 20-18 preseason finale loss to the Rams, head coach Jim Harbaugh offered a positive evaluation of quarterback DJ Uiagalelei's performance.
"I thought he did some good things," Harbaugh said. "Excited to look at the tape."
Uiagalelei delivered a performance that may have given him the upper hand for the backup spot to starter Justin Herbert. He entered the game for a late first-half drill and commanded the offense for the remainder of the second half. Uiagalelei showed solid composure, quick decision-making, and an ability to push the ball downfield
Stepping in with less than 30 seconds left in the second quarter, Uiagalelei instantly injected life into a stagnant offense. He completed back-to-back passes of 21 and 20 yards to set up a 49-yard field goal attempt, which kicker Cameron ******* er missed.
Later in the game, Uiagalelei threw a precise pass to tight end Evan Svoboda to successfully secure the two-point conversion and map the score to 20-18. With 3:24 remaining on the clock and the Chargers backed up at their own 1-yard line, Uiagalelei led a highly efficient drive into Rams territory. He found Liam Clifford for 13 yards and Gary Jennings for 24 yards to move past midfield.

#game

MOSCOW/WASHINGTON, Aug 26 (Reuters) - U.S. CIA Director John Ratcliffe spoke with Russian intelligence officials during a visit to Moscow but did not meet President Vladimir Putin, ‌the Kremlin said on Wednesday of a trip that U.S. President Donald Trump described ‌as "semi-routine."
Kremlin spokesman Dmitry Peskov told reporters Putin had been briefed on the outcome of Tuesday's visit, which came as the war in Ukraine drags on and as efforts to reach a lasting peace between the United States and Iran have stalled.
Peskov declined to say what had been discussed or to provide any further details.
"All I can tell you is that there have been contacts via the ‌security services. I can tell you ⁠that there have been no meetings with the Russian president. Naturally, President Putin is kept informed of everything without delay," said Peskov.
Trump, in ⁠a radio interview on Wednesday, did not say specifically why Ratcliffe had travelled to Moscow but said it could prove useful.

#president #putin

Merck & Co., Inc. (NYSE:MRK) jumped 12.6% to a record $152.20 on August 19 after a pivotal melanoma trial validated intismeran autogene, the individualized mRNA cancer therapy developed with Moderna. In the 1,137-patient Phase 3 INTerpath-001 study, intismeran plus Keytruda produced statistically significant and clinically meaningful improvements in recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone. No new safety concerns emerged. Investors are now asking whether intismeran can turn Keytruda from a drug approaching a patent cliff into the foundation of a personalized-cancer platform.
That distinction matters because Merck & Co., Inc. (NYSE:MRK) generated $31.68 billion from Keytruda and Keytruda Qlex in 2025, nearly half of the company's sales. In the U.S., biosimilar competition could begin after Keytruda's primary compound patent expires in December 2028, although biosimilars have already entered some smaller international markets. A successful combination could support continued use of the franchise without removing the need for other growth engines.
The bullish case for Merck & Co., Inc. (NYSE:MRK) is that intismeran adds a personalized immune response to a checkpoint inhibitor already embedded across oncology. The treatment is designed from the unique mutations in each patient's tumor and encodes as many as 34 neoantigens, training the immune system to recognize tumor cells while Keytruda removes a brake on the immune response.
Earlier Phase 2b data showed a 49% reduction in the risk of recurrence or death and a 59% reduction in distant metastasis or death at five years. Phase 3 confirmation makes the approach more credible for Merck & Co., Inc. (NYSE:MRK) beyond melanoma. The company is also studying intismeran combinations in non-small cell lung, bladder and renal-cell cancers. Success across several tumor types could create a portfolio of Keytruda combinations rather than a single indication.
That would give Merck & Co., Inc. (NYSE:MRK) another lifecycle-management tool alongside Keytruda Qlex and newer oncology ***** ets. It also strengthens the argument that Keytruda can remain commercially relevant after standalone pembrolizumab faces lower-priced competition.

#NYSE #tumor #cancer

Ukraine resumed drone attacks on Moscow overnight into Wednesday morning, the city's Mayor Sergey Sobyanin said, hours after the departure of the plane that carried CIA Director John Ratcliffe to Moscow for an unannounced visit on Tuesday morning.
Ukraine agreed to a U.S. request not to launch drone or missile strikes against Moscow during Ratcliffe's visit, a Ukrainian official told ABC News on Tuesday.
At least 10 drones were shot down while flying toward Moscow, Sobyanin said in a post to Telegram in the early hours of Wednesday morning. "Emergency services specialists are working at the crash site of the debris," the mayor said.
Russia's federal air transport agency, Rosaviatsiya, reported temporary flight restrictions at three of Moscow's four international airports -- Domodedovo, Zhukovsky and Vnukovo -- amid the overnight attacks. Ratcliffe's plane landed at Vnukovo on Tuesday morning and departed hours later, according to Flightradar24.
Alexander Zemlianichenko/AP Photo/Alexander Zemlianichenk - PHOTO: This file photo shows a view of Red Square in Moscow, Russia, on Aug. 24, 2026.

#moscow #tuesday #ukraine

Our **** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Stellantis just got another North America headache.
Trump's Canada tariff threat dragged down Ford and GM too, but Stellantis looks especially exposed because its Canadian factory footprint is already complicated, underused and politically sensitive.
President Donald Trump threatened to raise tariffs on Canadian cars, trucks, auto parts and steel to 50% from January 1, 2027, after US-Canada trade talks collapsed.
The market did not wait for the fine print. Stellantis shares fell roughly 3% in Paris and U.S.-linked trading, while Ford and General Motors also dropped as investors priced in higher costs for North American supply chains. US steelmakers moved the other way, with Cleveland-Cliffs, Nucor and Steel Dynamics rallying on the prospect that tariffs on Canadian steel could support domestic pricing.

#tell

Healthcare investors looking for long-term growth don't always have to choose between fast-growing companies and defensive businesses. Sometimes the more interesting decision is between two high-quality companies that are growing for entirely different reasons. Johnson & Johnson (NYSE:JNJ) continues to benefit from the breadth of its pharmaceutical and medical technology businesses, while Thermo Fisher's (NYSE:TMO) outlook increasingly depends on a recovery in life sciences spending after several difficult years.
Both companies reported encouraging results, but does steady diversification or an improving industry cycle offer the stronger long-term opportunity for investors? Let's take a look.
Johnson & Johnson's (NYSE:JNJ) pharmaceutical business was arguably the biggest contributor to its strong quarter, as it helped increase total sales, generating $16.38 billion in quarterly sales and exceeding **** ysts' estimate of $16.1 billion. The healthcare giant now expects its annual sales to be around $101.1 billion at the midpoint, compared with $100.8 billion ⁠previously. In another optimistic feat, it raised its adjusted earnings per share forecast to $11.68 at the midpoint, from a previous $11.55 per share.
The most impressive aspect for Johnson & Johnson (NYSE:JNJ), however, wasn't simply pharmaceutical growth but rather the company's ability to offset one of the largest patent cliffs in its portfolio, as it absorbed a significant patent-related decline in Stelara sales while still raising its full-year outlook. Revenue from Johnson & Johnson's (NYSE:JNJ) Stelara, which treats psoriasis, Crohn's disease, and other autoimmune conditions, dropped over 55% in the quarter to $740 million due to patent loss.
However, the company's cancer and newer immunology drugs can be seen countering this loss, as sales of Tremfya, its psoriasis and inflammatory bowel disease drug, rose 72.5% to $2 billion, considerably exceeding the estimate of $1.74 billion. Strong performance from newer drugs such as Tremfya suggests the company's pipeline is successfully offsetting losses from older products.

#billion #tremfya

Nucor, Steel Dynamics, Cleveland-Cliffs and Century Aluminum are likely winners from U.S.-Canada trade talks breaking down. All four stocks were higher early Monday after tumbling last week on the prospect of a Canada trade deal that would lower U.S. tariffs on steel and aluminum.
New 50% tariffs on $20 billion worth of Canadian goods, including liquor, electrical equipment and hockey gear, took effect on Saturday. Prime Minister Mark Carney vowed to retaliate "dollar for dollar," with its retaliatory tariffs starting Sept. 8 U.S. officials have threatened further escalation if that happens.
Earlier in the week, a trade deal seemed likely, with President Donald Trump late Tuesday postponing the new Canada tariffs, hours before they were set to kick in.
The U.S. and Canada seemed poised to reach a deal that would cut existing 50% tariffs on Canadian steel and aluminum to 25%, though steel imports would face limits. The U.S. also reportedly would cut duties on Canadian autos to 15% and scrap a 10% lumber tariffs.
The prospective of lower tariffs slammed U.S. steel stocks. Nucor (NUE) fell 5.85% on Wednesday and 9.4% for the week, tumbling from near a buy point to below its 50-day moving average. Steel Dynamics (STLD) dived 7.5% on Wednesday and 10.6% for the week, even with Friday's 4.4% bounce. STLD stock is now far below its 50-day line. Cleveland-Cliffs (CLF) sank 6% on Wednesday and 5.3% for the week, regaining its 50-day line on Friday.

#week